Brassicaceae

Intelinair Selected as Partner for USDA Climate-Smart Commodities Grant

Retrieved on:

Thursday, October 26, 2023

Intelinair announced that it has been selected to participate as a project partner in one of the USDA’s Partnerships for Climate-Smart Commodities grants.

Key Points:

Intelinair announced that it has been selected to participate as a project partner in one of the USDA’s Partnerships for Climate-Smart Commodities grants.
Intelinair is one of 17 company and university partners named to this pilot project utilizing its leading models and analytics to provide crop production analysis and crop yield estimation.
Camelina is an oilseed crop that can be used to produce ultra-low carbon renewable fuels.
Each acre of camelina can result in ~100 gallons of renewable diesel equivalent without causing land use change.

Yield10 Bioscience Begins 2021 Field Test and Seed Scale Up Program

Retrieved on:

Tuesday, July 13, 2021

Branches of biology, Plants, Plant morphology, Brassicaceae, Yield10 Bioscience, Staple foods, Potato, Camelina, Germplasm

WOBURN, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced it has completed planting of its 2021 Field Test and Seed Scale Up program at all contracted sites in the United States, Canada, and Argentina.

Key Points:

WOBURN, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced it has completed planting of its 2021 Field Test and Seed Scale Up program at all contracted sites in the United States, Canada, and Argentina.
Yield10s 2021 Field Test program is designed to test several varieties of elite Camelina, as well as seed yield and oil content traits.
Yield10 2021 Field Test and Seed Scale Up Program Summary:
Elite Camelina Germplasm: Yield10 is evaluating over 20 base germplasm lines including wildtype, doubled haploid, herbicide tolerant and disease resistant varieties at more than 10 sites across the U.S., Canada, and Argentina.
The seed scale up program is designed to generate field-grown seed for subsequent field studies as well as to build seed inventory to enable planting at increasing scale.

Global Camelina Oil Market Report 2021-2025 - Rising Demand for Functional Foods and the Emergence of Online Grocery Stores - ResearchAndMarkets.com

Retrieved on:

Tuesday, July 6, 2021

Food, Beverage, Agriculture, Natural Resources, Cosmetics, Retail, Brassicaceae, Camelina, Marketplace, Market, Biofuels

The report on the camelina oil market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Key Points:

The report on the camelina oil market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
This study identifies the increasing demand for biofuels as one of the prime reasons driving the camelina oil market growth during the next few years.
Also, the rising demand for functional foods and the emergence of online grocery stores will lead to sizable demand in the market.

Yield10 Bioscience Announces Two New Hires as Camelina Business Plan Advances

Retrieved on:

Tuesday, June 29, 2021

Articles, Business intelligence, Business, Economy, Yield10 Bioscience, Brassicaceae, Formal sciences, Camelina, Business analytics, Analytics, Renegar

WOBURN, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced two new hires.

Key Points:

WOBURN, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced two new hires.
In this new role, Dr. Renegar will be responsible for business analytics and project management as well as supporting Yield10s business development, supply chain development, and seed operations activities.
Nick brings to this role a strong background in food safety and global supply chain analytics, areas we will be focused on as we advance Yield10s Camelina business plan, said Dr.
Yield10 assumes no obligation to update any forward-looking information contained in this press release or with respect to the matters described herein.

Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present on Advances Using Camelina Platform to Produce PHA Bioplastic at 2021 Synthetic Biology: Engineering, Evolution and Design Virtual Conference

Retrieved on:

Wednesday, June 16, 2021

Articles, Branches of biology, Biology, Yield10 Bioscience, Brassicaceae, Camelina, Synthetic biology, Seed

WOBURN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the 2021 Synthetic Biology: Engineering, Evolution & Design (SEED) conference, taking place in a virtual format June 15 through June 18, 2021.

Key Points:

WOBURN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the 2021 Synthetic Biology: Engineering, Evolution & Design (SEED) conference, taking place in a virtual format June 15 through June 18, 2021.
In 2020, several Camelina lines were grown in small plots at field test sites in the U.S. and Canada.
Compared to control plants, the engineered PHA Camelina lines emerged and matured later, but once established exhibited good vigor, branching, flowering and seed set.
Learn more about the 2021 Synthetic Biology: Engineering, Evolution & Design (SEED) conference on the conference website .

Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors

Retrieved on:

Monday, June 14, 2021

Biotechnology, Pharmaceutical, Health, Other Health, Aurinia, Brassicaceae, Names, Balakrishna, Indian names, Humans

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Companys Board of Directors effective June 14, 2021.

Key Points:

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Companys Board of Directors effective June 14, 2021.
View the full release here: https://www.businesswire.com/news/home/20210614005185/en/
Dr. Brinda Balakrishnan, newly appointed Director to the Aurinia Pharmaceuticals Board.
(Photo: Business Wire)
On behalf of the entire Company, it is an honor to welcome Dr. Balakrishnan to Aurinias Board of Directors, commented Peter Greenleaf, President and Chief Executive Officer of Aurinia.
I am delighted to join the Board of Directors of Aurinia, said Dr. Balakrishnan.

Ag-West Bio: Research Snapshots Shed Light on the Diverse Field Crops Cluster Research Activities

Retrieved on:

Wednesday, April 28, 2021

Science, Other Science, Agriculture, Biotechnology, Research, Natural Resources, Health, Other Natural Resources, Agriculture, Crops, Brassicaceae, Staple foods, Biofuels, Non-food crops, Camelina, Quinoa, Hemp, Agronomy

b"A unique alliance has given seven high-potential prairie crops some much-deserved research attention.

Key Points:

b"A unique alliance has given seven high-potential prairie crops some much-deserved research attention.
The Diverse Field Crops Cluster (DFCC) supports the research and development of camelina, canary seed, flax, hemp, mustard, quinoa, and sunflower.\nDFCC activities focus on agronomy, variety development, and value-add initiatives.
A new series of \xe2\x80\x98research snapshots\xe2\x80\x99 describe the 16 different activities at the half-way mark in the five-year program.
\xe2\x80\x9cThis is an important program that aligns industry and researchers and opens new opportunities for producers.\xe2\x80\x9d\nDFCC Project Manager Carol Ann Patterson says the snapshots illustrate the hard work of researchers, cluster members and industry partners.

Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences

Retrieved on:

Tuesday, March 2, 2021

Biotechnology, Pharmaceutical, Health, Medical Supplies, Aurinia, Brassicaceae, Fireside chats, 20th century in the United States, The United States

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) today announced that members of the executive management team will participate in multiple upcoming investor conferences including the:

Key Points:

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) today announced that members of the executive management team will participate in multiple upcoming investor conferences including the:
Cowen 41st Annual virtual Healthcare Conference fireside chat on Thursday, March 4, 2021 at 2:10 p.m.
ET;
H.C. Wainwright Global Life Sciences Conference fireside chat available on Tuesday, March 9, 2021 at 7:00 a.m.
ET; and
Oppenheimers 31st Annual Healthcare Conference presentation on Wednesday, March 17, 2021 at 10:40 a.m.
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need.

Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights

Retrieved on:

Wednesday, February 24, 2021

Biotechnology, Pharmaceutical, Health, Medical Supplies, Aurinia, Brassicaceae, Lupus Nephritis, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today issued its financial results for the fourth quarter and year ended December 31, 2020.

Key Points:

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today issued its financial results for the fourth quarter and year ended December 31, 2020.
Financial Results for the Year Ended December 31, 2020
For the year ended December 31, 2020, Aurinia recorded a consolidated net loss of $102.7 million or $0.87 per common share.
Financial Results for the Fourth Quarter Ended December 31, 2020
For the three months ended December 31, 2020, Aurinia recorded a consolidated net loss of $8.1 million or $0.05 per common share.
Aurinia will host a conference call and webcast to discuss the fourth quarter and year ended December 31, 2020 financial results today, Wednesday, February 24, 2020 at 4:30 p.m.

Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021

Retrieved on:

Wednesday, February 17, 2021

Biotechnology, Pharmaceutical, Health, Aurinia, Brassicaceae, NASDAQ, Finance

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close.

Key Points:

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close.
Aurinias management team will host a conference call to discuss the Companys financial results and to provide a general business update.
The conference call and webcast is scheduled for February 24, 2021 at 4:30pm ET.
An audio webcast can be accessed under "News/Events through the Investors section of the Aurinia corporate website at www.auriniapharma.com .